Efficacy and safety outcomes of cataract surgery in survivors of ebola virus disease: 12-month results from the PREVAIL VII study

Allen O. Eghrari; Jessica G. Shantha; Robin D. Ross; Collin Van Ryn; Ian Crozier; Brent Hayek; Dan Gradin; Ben Roberts; S. Grace Prakalapakorn; Fred Amegashie; Kumar Nishant; Gurcharan Singh; Robert Dolo; John Fankhauser; Bryn Burkholder; James Pettitt; Robin Gross; Tyler Brady; Bonnie Dighero-Kemp; Cavan Reilly; Lisa Hensley; Elizabeth Higgs; Steven Yeh; Rachel J. Bishop

doi:10.1167/tvst.10.1.32

Efficacy and safety outcomes of cataract surgery in survivors of ebola virus disease: 12-month results from the PREVAIL VII study

Allen O. Eghrari, Jessica G. Shantha, Robin D. Ross, Collin Van Ryn, Ian Crozier, Brent Hayek, Dan Gradin, Ben Roberts, S. Grace Prakalapakorn, Fred Amegashie, Kumar Nishant, Gurcharan Singh, Robert Dolo, John Fankhauser, Bryn Burkholder, James Pettitt, Robin Gross, Tyler Brady, Bonnie Dighero-Kemp, Cavan ReillyLisa Hensley, Elizabeth Higgs, Steven Yeh, Rachel J. Bishop

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

Purpose: In survivors of Ebola virus disease (EVD), intraocular viral persistence raises questions about the timing and safety of cataract surgery. To the best of our knowledge, this is the first controlled study evaluating Ebola virus persistence and cataract surgery safety and outcomes in EVD survivors.

Methods: Seropositive EVD survivors and seronegative controls with vision worse than 20/40 from cataract and without active intraocular inflammation were enrolled. Aqueous humor from survivors was tested with reverse transcription-polymerase chain reaction for Ebola viral RNA. Participants underwent manual small-incision cataract surgery and 1 year of follow-up examinations.

Results: Twenty-two eyes of 22 survivors and 12 eyes of eight controls underwent cataract surgery. All of the aqueous samples tested negative for Ebola viral RNA. Median visual acuity improved from 20/200 at baseline to 20/25 at 1 year in survivors and from count fingers to 20/50 in controls (overall, P < 0.001; between groups, P = 0.07). After a 1-month course of topical corticosteroids, 55% of survivors and 67% of controls demonstrated at least 1+ anterior chamber cell. Twelve months after surgery, optical coherence tomography revealed a median increase in macular central subfield thickness of 42 µm compared with baseline (overall, P = 0.029; between groups, P = 0.995).

Conclusions: EVD survivors and controls demonstrated significant visual improvement from cataract surgery. The persistence of intraocular inflammation highlights the importance of follow-up. The absence of detectable intraocular Ebola viral RNA provides guidance regarding the safety of eye surgery in Ebola survivors.

Translational Relevance: These findings demonstrate the safety and efficacy of cataract surgery in Ebola survivors and will inform ocular surgery guidelines in this population.

Original language	English (US)
Article number	32
Pages (from-to)	1-12
Number of pages	12
Journal	Translational Vision Science and Technology
Volume	10
Issue number	1
DOIs	https://doi.org/10.1167/tvst.10.1.32
State	Published - Jan 2021

Bibliographical note

Funding Information:
The authors thank Beth Thompson and Karen Daniels of Samaritan’s Purse International Relief for surgical planning and onsite surgical logistics and operations, and we thank Samaritan’s Purse for provision of surgical equipment and supplies. We thank Eternal Love Winning Africa Hospital and staff in Monrovia, Liberia, for support to surgical operations and providing accommodations to patients. We thank the L V Prasad Eye Institute in Hyderabad, India and L V Prasad Eye Institute’s Liberian Eye Center in Monrovia, Liberia, for help with providing postoperative care to patients. We thank the Liberian Institute for Biomedical Research laboratory in Monrovia, Liberia, for sample processing. We thank Jeff Sanderson of John Snow Incorporated for help with project coordination. We thank the US Agency for International Development for support through the Ebola Transmission Prevention and Survivor Services Program. We thank Catherine Gargu, Yassah Sosu, Jennie Sackor, Precious Cooper, Augustine Wallace, Ruth Nyain, Famatta Kamara, James Mulbah, Mercy Bowulo, Zipporah Cheburet, Dennis Kipkorir, Emily Chepkoech, Robert Koskey, John Troke, Alison Jordan, RickWood, Bev Kauffeldt, and Emmanuel Nyah for help caring for and communicating with study participants. Finally, we thank the SocialMobilization Team for coordinating participant visits. Supported in part by the Division of Intramural Research of the National Institute of Allergy and Infectious Disease (NIAID) and the National Eye Institute (NEI) of the National Institutes of Health; by the NEI (award numbers K23 EY030158, JGS; RO1 EY029594, SY); by the National Cancer Institute (Contract No. HHSN261200800001E, IC); and by an American Society of Cataract and Refractive Surgery Foundation grant (“Cataract Surgical Outcomes Among Survivors of Ebola Virus Disease,” AOE). Supported by an unrestricted departmental grant from Research to Prevent Blindness to the Emory Eye Center, Emory University School of Medicine. NIAID and NEI participated in the design of the study and conducting the study. Other sponsors and funding organizations had no role in the design or conduct of this research.

Funding Information:
Supported by an unrestricted departmental grant from Research to Prevent Blindness to the Emory Eye Center, Emory University School of Medicine. NIAID and NEI participated in the design of the study and conducting the study. Other sponsors and funding organizations had no role in the design or conduct of this research.

Funding Information:
The authors thank Beth Thompson and Karen Daniels of Samaritan’s Purse International Relief for surgical planning and onsite surgical logistics and operations, and we thank Samaritan’s Purse for provision of surgical equipment and supplies. We thank Eternal Love Winning Africa Hospital and staff in Monrovia, Liberia, for support to surgical operations and providing accommodations to patients. We thank the L V Prasad Eye Institute in Hyderabad, India and L V Prasad Eye Institute’s Liberian Eye Center in Monrovia, Liberia, for help with providing postoperative care to patients. We thank the Liberian Institute for Biomedical Research laboratory in Monrovia, Liberia, for sample processing. We thank Jeff Sanderson of John Snow Incorporated for help with project coordination. We thank the US Agency for International Development for support through the Ebola Transmission Prevention and Survivor Services Program. We thank Catherine Gargu, Yassah Sosu, Jennie Sackor, Precious Cooper, Augustine Wallace, Ruth Nyain, Famatta Kamara, James Mulbah, Mercy Bowulo, Zipporah Cheburet, Dennis Kipkorir, Emily Chepkoech, Robert Koskey, John Troke, Alison Jordan, Rick Wood, Bev Kauffeldt, and Emmanuel Nyah for help caring for and communicating with study participants. Finally, we thank the Social Mobilization Team for coordinating participant visits.

Funding Information:
Supported in part by the Division of Intramural Research of the National Institute of Allergy and Infectious Disease (NIAID) and the National Eye Institute (NEI) of the National Institutes of Health; by the NEI (award numbers K23 EY030158, JGS; RO1 EY029594, SY); by the National Cancer Institute (Contract No. HHSN261200800001E, IC); and by an American Society of Cataract and Refractive Surgery Foundation grant (“Cataract Surgical Outcomes Among Survivors of Ebola Virus Disease,” AOE).

Publisher Copyright:
© 2021 The Authors.

Keywords

Cataract surgery
Ebola virus disease
Manual small incision cataract surgery
Uveitis
Ebolavirus
Cataract
Cataract Extraction
Humans
Hemorrhagic Fever, Ebola/complications
Survivors

PubMed: MeSH publication types

Research Support, Non-U.S. Gov't
Research Support, N.I.H., Intramural
Journal Article
Research Support, N.I.H., Extramural

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1167/tvst.10.1.32

Find It

Find It at U of M Libraries

Cite this

Eghrari, A. O., Shantha, J. G., Ross, R. D., Van Ryn, C., Crozier, I., Hayek, B., Gradin, D., Roberts, B., Prakalapakorn, S. G., Amegashie, F., Nishant, K., Singh, G., Dolo, R., Fankhauser, J., Burkholder, B., Pettitt, J., Gross, R., Brady, T., Dighero-Kemp, B., ... Bishop, R. J. (2021). Efficacy and safety outcomes of cataract surgery in survivors of ebola virus disease: 12-month results from the PREVAIL VII study. Translational Vision Science and Technology, 10(1), 1-12. Article 32. https://doi.org/10.1167/tvst.10.1.32

Eghrari, AO, Shantha, JG, Ross, RD, Van Ryn, C, Crozier, I, Hayek, B, Gradin, D, Roberts, B, Prakalapakorn, SG, Amegashie, F, Nishant, K, Singh, G, Dolo, R, Fankhauser, J, Burkholder, B, Pettitt, J, Gross, R, Brady, T, Dighero-Kemp, B, Reilly, C, Hensley, L, Higgs, E, Yeh, S & Bishop, RJ 2021, 'Efficacy and safety outcomes of cataract surgery in survivors of ebola virus disease: 12-month results from the PREVAIL VII study', Translational Vision Science and Technology, vol. 10, no. 1, 32, pp. 1-12. https://doi.org/10.1167/tvst.10.1.32

@article{7d96af978acf42f69066cd3f79069edc,

title = "Efficacy and safety outcomes of cataract surgery in survivors of ebola virus disease: 12-month results from the PREVAIL VII study",

abstract = "Purpose: In survivors of Ebola virus disease (EVD), intraocular viral persistence raises questions about the timing and safety of cataract surgery. To the best of our knowledge, this is the first controlled study evaluating Ebola virus persistence and cataract surgery safety and outcomes in EVD survivors.Methods: Seropositive EVD survivors and seronegative controls with vision worse than 20/40 from cataract and without active intraocular inflammation were enrolled. Aqueous humor from survivors was tested with reverse transcription-polymerase chain reaction for Ebola viral RNA. Participants underwent manual small-incision cataract surgery and 1 year of follow-up examinations.Results: Twenty-two eyes of 22 survivors and 12 eyes of eight controls underwent cataract surgery. All of the aqueous samples tested negative for Ebola viral RNA. Median visual acuity improved from 20/200 at baseline to 20/25 at 1 year in survivors and from count fingers to 20/50 in controls (overall, P < 0.001; between groups, P = 0.07). After a 1-month course of topical corticosteroids, 55% of survivors and 67% of controls demonstrated at least 1+ anterior chamber cell. Twelve months after surgery, optical coherence tomography revealed a median increase in macular central subfield thickness of 42 µm compared with baseline (overall, P = 0.029; between groups, P = 0.995). Conclusions: EVD survivors and controls demonstrated significant visual improvement from cataract surgery. The persistence of intraocular inflammation highlights the importance of follow-up. The absence of detectable intraocular Ebola viral RNA provides guidance regarding the safety of eye surgery in Ebola survivors.Translational Relevance: These findings demonstrate the safety and efficacy of cataract surgery in Ebola survivors and will inform ocular surgery guidelines in this population.",

keywords = "Cataract surgery, Ebola virus disease, Manual small incision cataract surgery, Uveitis, Ebolavirus, Cataract, Cataract Extraction, Humans, Hemorrhagic Fever, Ebola/complications, Survivors",

author = "Eghrari, {Allen O.} and Shantha, {Jessica G.} and Ross, {Robin D.} and {Van Ryn}, Collin and Ian Crozier and Brent Hayek and Dan Gradin and Ben Roberts and Prakalapakorn, {S. Grace} and Fred Amegashie and Kumar Nishant and Gurcharan Singh and Robert Dolo and John Fankhauser and Bryn Burkholder and James Pettitt and Robin Gross and Tyler Brady and Bonnie Dighero-Kemp and Cavan Reilly and Lisa Hensley and Elizabeth Higgs and Steven Yeh and Bishop, {Rachel J.}",

note = "Funding Information: The authors thank Beth Thompson and Karen Daniels of Samaritan{\textquoteright}s Purse International Relief for surgical planning and onsite surgical logistics and operations, and we thank Samaritan{\textquoteright}s Purse for provision of surgical equipment and supplies. We thank Eternal Love Winning Africa Hospital and staff in Monrovia, Liberia, for support to surgical operations and providing accommodations to patients. We thank the L V Prasad Eye Institute in Hyderabad, India and L V Prasad Eye Institute{\textquoteright}s Liberian Eye Center in Monrovia, Liberia, for help with providing postoperative care to patients. We thank the Liberian Institute for Biomedical Research laboratory in Monrovia, Liberia, for sample processing. We thank Jeff Sanderson of John Snow Incorporated for help with project coordination. We thank the US Agency for International Development for support through the Ebola Transmission Prevention and Survivor Services Program. We thank Catherine Gargu, Yassah Sosu, Jennie Sackor, Precious Cooper, Augustine Wallace, Ruth Nyain, Famatta Kamara, James Mulbah, Mercy Bowulo, Zipporah Cheburet, Dennis Kipkorir, Emily Chepkoech, Robert Koskey, John Troke, Alison Jordan, RickWood, Bev Kauffeldt, and Emmanuel Nyah for help caring for and communicating with study participants. Finally, we thank the SocialMobilization Team for coordinating participant visits. Supported in part by the Division of Intramural Research of the National Institute of Allergy and Infectious Disease (NIAID) and the National Eye Institute (NEI) of the National Institutes of Health; by the NEI (award numbers K23 EY030158, JGS; RO1 EY029594, SY); by the National Cancer Institute (Contract No. HHSN261200800001E, IC); and by an American Society of Cataract and Refractive Surgery Foundation grant (“Cataract Surgical Outcomes Among Survivors of Ebola Virus Disease,” AOE). Supported by an unrestricted departmental grant from Research to Prevent Blindness to the Emory Eye Center, Emory University School of Medicine. NIAID and NEI participated in the design of the study and conducting the study. Other sponsors and funding organizations had no role in the design or conduct of this research. Funding Information: Supported by an unrestricted departmental grant from Research to Prevent Blindness to the Emory Eye Center, Emory University School of Medicine. NIAID and NEI participated in the design of the study and conducting the study. Other sponsors and funding organizations had no role in the design or conduct of this research. Funding Information: The authors thank Beth Thompson and Karen Daniels of Samaritan{\textquoteright}s Purse International Relief for surgical planning and onsite surgical logistics and operations, and we thank Samaritan{\textquoteright}s Purse for provision of surgical equipment and supplies. We thank Eternal Love Winning Africa Hospital and staff in Monrovia, Liberia, for support to surgical operations and providing accommodations to patients. We thank the L V Prasad Eye Institute in Hyderabad, India and L V Prasad Eye Institute{\textquoteright}s Liberian Eye Center in Monrovia, Liberia, for help with providing postoperative care to patients. We thank the Liberian Institute for Biomedical Research laboratory in Monrovia, Liberia, for sample processing. We thank Jeff Sanderson of John Snow Incorporated for help with project coordination. We thank the US Agency for International Development for support through the Ebola Transmission Prevention and Survivor Services Program. We thank Catherine Gargu, Yassah Sosu, Jennie Sackor, Precious Cooper, Augustine Wallace, Ruth Nyain, Famatta Kamara, James Mulbah, Mercy Bowulo, Zipporah Cheburet, Dennis Kipkorir, Emily Chepkoech, Robert Koskey, John Troke, Alison Jordan, Rick Wood, Bev Kauffeldt, and Emmanuel Nyah for help caring for and communicating with study participants. Finally, we thank the Social Mobilization Team for coordinating participant visits. Funding Information: Supported in part by the Division of Intramural Research of the National Institute of Allergy and Infectious Disease (NIAID) and the National Eye Institute (NEI) of the National Institutes of Health; by the NEI (award numbers K23 EY030158, JGS; RO1 EY029594, SY); by the National Cancer Institute (Contract No. HHSN261200800001E, IC); and by an American Society of Cataract and Refractive Surgery Foundation grant (“Cataract Surgical Outcomes Among Survivors of Ebola Virus Disease,” AOE). Publisher Copyright: {\textcopyright} 2021 The Authors.",

year = "2021",

month = jan,

doi = "10.1167/tvst.10.1.32",

language = "English (US)",

volume = "10",

pages = "1--12",

journal = "Translational Vision Science and Technology",

issn = "2164-2591",

publisher = "Association for Research in Vision and Ophthalmology Inc.",

number = "1",

}

TY - JOUR

T1 - Efficacy and safety outcomes of cataract surgery in survivors of ebola virus disease

T2 - 12-month results from the PREVAIL VII study

AU - Eghrari, Allen O.

AU - Shantha, Jessica G.

AU - Ross, Robin D.

AU - Van Ryn, Collin

AU - Crozier, Ian

AU - Hayek, Brent

AU - Gradin, Dan

AU - Roberts, Ben

AU - Prakalapakorn, S. Grace

AU - Amegashie, Fred

AU - Nishant, Kumar

AU - Singh, Gurcharan

AU - Dolo, Robert

AU - Fankhauser, John

AU - Burkholder, Bryn

AU - Pettitt, James

AU - Gross, Robin

AU - Brady, Tyler

AU - Dighero-Kemp, Bonnie

AU - Reilly, Cavan

AU - Hensley, Lisa

AU - Higgs, Elizabeth

AU - Yeh, Steven

AU - Bishop, Rachel J.

N1 - Funding Information: The authors thank Beth Thompson and Karen Daniels of Samaritan’s Purse International Relief for surgical planning and onsite surgical logistics and operations, and we thank Samaritan’s Purse for provision of surgical equipment and supplies. We thank Eternal Love Winning Africa Hospital and staff in Monrovia, Liberia, for support to surgical operations and providing accommodations to patients. We thank the L V Prasad Eye Institute in Hyderabad, India and L V Prasad Eye Institute’s Liberian Eye Center in Monrovia, Liberia, for help with providing postoperative care to patients. We thank the Liberian Institute for Biomedical Research laboratory in Monrovia, Liberia, for sample processing. We thank Jeff Sanderson of John Snow Incorporated for help with project coordination. We thank the US Agency for International Development for support through the Ebola Transmission Prevention and Survivor Services Program. We thank Catherine Gargu, Yassah Sosu, Jennie Sackor, Precious Cooper, Augustine Wallace, Ruth Nyain, Famatta Kamara, James Mulbah, Mercy Bowulo, Zipporah Cheburet, Dennis Kipkorir, Emily Chepkoech, Robert Koskey, John Troke, Alison Jordan, RickWood, Bev Kauffeldt, and Emmanuel Nyah for help caring for and communicating with study participants. Finally, we thank the SocialMobilization Team for coordinating participant visits. Supported in part by the Division of Intramural Research of the National Institute of Allergy and Infectious Disease (NIAID) and the National Eye Institute (NEI) of the National Institutes of Health; by the NEI (award numbers K23 EY030158, JGS; RO1 EY029594, SY); by the National Cancer Institute (Contract No. HHSN261200800001E, IC); and by an American Society of Cataract and Refractive Surgery Foundation grant (“Cataract Surgical Outcomes Among Survivors of Ebola Virus Disease,” AOE). Supported by an unrestricted departmental grant from Research to Prevent Blindness to the Emory Eye Center, Emory University School of Medicine. NIAID and NEI participated in the design of the study and conducting the study. Other sponsors and funding organizations had no role in the design or conduct of this research. Funding Information: Supported by an unrestricted departmental grant from Research to Prevent Blindness to the Emory Eye Center, Emory University School of Medicine. NIAID and NEI participated in the design of the study and conducting the study. Other sponsors and funding organizations had no role in the design or conduct of this research. Funding Information: The authors thank Beth Thompson and Karen Daniels of Samaritan’s Purse International Relief for surgical planning and onsite surgical logistics and operations, and we thank Samaritan’s Purse for provision of surgical equipment and supplies. We thank Eternal Love Winning Africa Hospital and staff in Monrovia, Liberia, for support to surgical operations and providing accommodations to patients. We thank the L V Prasad Eye Institute in Hyderabad, India and L V Prasad Eye Institute’s Liberian Eye Center in Monrovia, Liberia, for help with providing postoperative care to patients. We thank the Liberian Institute for Biomedical Research laboratory in Monrovia, Liberia, for sample processing. We thank Jeff Sanderson of John Snow Incorporated for help with project coordination. We thank the US Agency for International Development for support through the Ebola Transmission Prevention and Survivor Services Program. We thank Catherine Gargu, Yassah Sosu, Jennie Sackor, Precious Cooper, Augustine Wallace, Ruth Nyain, Famatta Kamara, James Mulbah, Mercy Bowulo, Zipporah Cheburet, Dennis Kipkorir, Emily Chepkoech, Robert Koskey, John Troke, Alison Jordan, Rick Wood, Bev Kauffeldt, and Emmanuel Nyah for help caring for and communicating with study participants. Finally, we thank the Social Mobilization Team for coordinating participant visits. Funding Information: Supported in part by the Division of Intramural Research of the National Institute of Allergy and Infectious Disease (NIAID) and the National Eye Institute (NEI) of the National Institutes of Health; by the NEI (award numbers K23 EY030158, JGS; RO1 EY029594, SY); by the National Cancer Institute (Contract No. HHSN261200800001E, IC); and by an American Society of Cataract and Refractive Surgery Foundation grant (“Cataract Surgical Outcomes Among Survivors of Ebola Virus Disease,” AOE). Publisher Copyright: © 2021 The Authors.

PY - 2021/1

Y1 - 2021/1

N2 - Purpose: In survivors of Ebola virus disease (EVD), intraocular viral persistence raises questions about the timing and safety of cataract surgery. To the best of our knowledge, this is the first controlled study evaluating Ebola virus persistence and cataract surgery safety and outcomes in EVD survivors.Methods: Seropositive EVD survivors and seronegative controls with vision worse than 20/40 from cataract and without active intraocular inflammation were enrolled. Aqueous humor from survivors was tested with reverse transcription-polymerase chain reaction for Ebola viral RNA. Participants underwent manual small-incision cataract surgery and 1 year of follow-up examinations.Results: Twenty-two eyes of 22 survivors and 12 eyes of eight controls underwent cataract surgery. All of the aqueous samples tested negative for Ebola viral RNA. Median visual acuity improved from 20/200 at baseline to 20/25 at 1 year in survivors and from count fingers to 20/50 in controls (overall, P < 0.001; between groups, P = 0.07). After a 1-month course of topical corticosteroids, 55% of survivors and 67% of controls demonstrated at least 1+ anterior chamber cell. Twelve months after surgery, optical coherence tomography revealed a median increase in macular central subfield thickness of 42 µm compared with baseline (overall, P = 0.029; between groups, P = 0.995). Conclusions: EVD survivors and controls demonstrated significant visual improvement from cataract surgery. The persistence of intraocular inflammation highlights the importance of follow-up. The absence of detectable intraocular Ebola viral RNA provides guidance regarding the safety of eye surgery in Ebola survivors.Translational Relevance: These findings demonstrate the safety and efficacy of cataract surgery in Ebola survivors and will inform ocular surgery guidelines in this population.

AB - Purpose: In survivors of Ebola virus disease (EVD), intraocular viral persistence raises questions about the timing and safety of cataract surgery. To the best of our knowledge, this is the first controlled study evaluating Ebola virus persistence and cataract surgery safety and outcomes in EVD survivors.Methods: Seropositive EVD survivors and seronegative controls with vision worse than 20/40 from cataract and without active intraocular inflammation were enrolled. Aqueous humor from survivors was tested with reverse transcription-polymerase chain reaction for Ebola viral RNA. Participants underwent manual small-incision cataract surgery and 1 year of follow-up examinations.Results: Twenty-two eyes of 22 survivors and 12 eyes of eight controls underwent cataract surgery. All of the aqueous samples tested negative for Ebola viral RNA. Median visual acuity improved from 20/200 at baseline to 20/25 at 1 year in survivors and from count fingers to 20/50 in controls (overall, P < 0.001; between groups, P = 0.07). After a 1-month course of topical corticosteroids, 55% of survivors and 67% of controls demonstrated at least 1+ anterior chamber cell. Twelve months after surgery, optical coherence tomography revealed a median increase in macular central subfield thickness of 42 µm compared with baseline (overall, P = 0.029; between groups, P = 0.995). Conclusions: EVD survivors and controls demonstrated significant visual improvement from cataract surgery. The persistence of intraocular inflammation highlights the importance of follow-up. The absence of detectable intraocular Ebola viral RNA provides guidance regarding the safety of eye surgery in Ebola survivors.Translational Relevance: These findings demonstrate the safety and efficacy of cataract surgery in Ebola survivors and will inform ocular surgery guidelines in this population.

KW - Cataract surgery

KW - Ebola virus disease

KW - Manual small incision cataract surgery

KW - Uveitis

KW - Ebolavirus

KW - Cataract

KW - Cataract Extraction

KW - Humans

KW - Hemorrhagic Fever, Ebola/complications

KW - Survivors

UR - http://www.scopus.com/inward/record.url?scp=85100709972&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85100709972&partnerID=8YFLogxK

U2 - 10.1167/tvst.10.1.32

DO - 10.1167/tvst.10.1.32

M3 - Article

C2 - 33520427

AN - SCOPUS:85100709972

SN - 2164-2591

VL - 10

SP - 1

EP - 12

JO - Translational Vision Science and Technology

JF - Translational Vision Science and Technology

IS - 1

M1 - 32

ER -

Efficacy and safety outcomes of cataract surgery in survivors of ebola virus disease: 12-month results from the PREVAIL VII study

Abstract

Bibliographical note

Keywords

PubMed: MeSH publication types

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this